Connecticut and Texas Last to Join Others in Testing for Life-threatening Disease
Site Search
The U.S. Food and Drug Administration has approved the use of Kalydeco® (ivacaftor) for infants with cystic fibrosis as young as four months who have certain mutations.
On Mar. 11, the Cystic Fibrosis Foundation presented the Alex, Jena and Dream Big Awards to leaders in the CF community for their dedication to the Foundation's mission of finding a cure.
As a mother of three sons with cystic fibrosis, Mary along with her husband, Harry, was determined to do all she could to find a cure.
The U.S. Food and Drug Administration (FDA) today expanded its approval of three CFTR modulators to include additional people with CF who have certain rare mutations. The approval enables more than 600 individuals with CF who were not previously eligible for modulators to access drugs that treat the underlying cause of their disease for the first time.
The Cystic Fibrosis Foundation announced the appointment of Marc Ginsky as executive vice president and chief operating officer. Mr. Ginsky will oversee the Foundation's day-to-day operations with a focus on field management, information technology and the Foundation's infrastructure.
As part of its Building Trust Video series, the Better Business Bureau's (BBB) Wise Giving Alliance is featuring an interview with Preston W. Campbell, III, M.D., president and CEO of the Cystic Fibrosis Foundation.